Ticker Launch
Sign inTry it free

SPAC · Merger completed

Moringa Acquisition Corp

Business combination with Silexion Therapeutics Ltd.

Moringa Acquisition Corp is a blank-check company (SPAC) that raised $100M in its initial public offering on Feb 17, 2021, listing on Nasdaq Capital Market. It completed its business combination with Silexion Therapeutics Ltd. on Aug 15, 2024; the combined company is Silexion Therapeutics Corp (SLXN). McFarland Dewey led the IPO, with EF Hutton. McDermott Will & Emery advised the SPAC and Graubard Miller advised the underwriters on the IPO.

Silexion Therapeutics Ltd. is a clinical-stage, oncology-focused biotechnology company developing treatments for solid tumor cancers that carry the mutated KRAS oncogene. It has conducted a Phase 2a trial, and is the target of a combination with Moringa Acquisition Corp.

Status
Merger completed
IPO date
Feb 17, 2021
IPO size
$100M
IPO exchange
Nasdaq Capital Market
Target
Silexion Therapeutics Ltd.
Announced
Feb 26, 2024
Closed
Aug 15, 2024
Combined company
Silexion Therapeutics Corp (SLXN)
IPO underwriters
McFarland Dewey and EF Hutton
SPAC counsel (IPO)
McDermott Will & Emery and Maples and Calder
Underwriters' counsel (IPO)
Graubard Miller

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other deSPACs that closed in 2024